This MAX MDR-TB panel is included in WHO guidelines and now clinicians can use the test to simultaneously detect bacteria that cause tuberculosis (TB)
To enable clinicians to rapidly test for TB and multidrug resistance as a first-line test, BD Diagnostics, a segment of BD Lifesciences (Becton, Dickinson, and Company) has introduced the BD MAX molecular diagnostic system and availability of the BD MAX MDR-TB panel in India.
This MAX MDR-TB panel is included in WHO guidelines and now clinicians can use the test to simultaneously detect bacteria that cause tuberculosis (TB) and determine if the bacteria contain mutations associated with resistance to two important first-line drugs-Isoniazid (INH) and Rifampicin (RIF) respectively. This molecular test enhances the information available to direct the optimal treatment for patients and rules out the need for a separate test for isoniazid (INH) detection.
The BD MAX System is automated platform that performs nucleic acid extraction and real-time PCR and empowers laboratories to automate their unique internally developed molecular assays, while accessing a rich and growing menu of world-class assays.
- Advertisement -